Abstract 921P
Background
Incidence of oropharyngeal squamous cell carcinoma (OPSCC) increases due to rise in human papilloma virus (HPV) related cancers. The tumor microenvironment (TME) of HPV+ OPSCC is characterized as more immune tolerant, with higher density of tumor-infiltrating lymphocytes (TILs). The role of tumor-associated macrophages (TAMs) remains unclear. M2-like TAMs are correlated with impaired overall survival (OS) in other tumor types. This study characterizes the prognostic impact of M2-like TAMs in OPSCC.
Methods
Fifty-eight patients with primary OPSCC, undergoing definite treatment (surgery, radiotherapy, chemoradiotherapy or a combination), were included. FFPE samples were stained for P16, TILs (CD3, CD8, FOXP3) and TAMs (CD68, CD163 and CD206) markers. Semi-quantitative assessment of each marker, in the tumor nest(t) and stroma(s), was executed by a board certified pathologist. Survival estimates were calculated via the Kaplan-Meier method using the log-rank test, using the ad hoc calculated cut-off point. Uni- and multivariate analysis were performed via cox proportional hazard model.
Results
The median density of sCD3, sCD8, tCD68 and sCD206 TAMs was higher in P16+, compared to P16–, whereas FOXP3 and CD163 infiltration was similar according to P16 status. In univariate analysis, tumors with high leukocyte infiltrates (sTIL, sCD8, tCD8, sFOXP3, tCD68, sCD206) had a better overall survival (OS), whereas sTIL-high and tCD8-high were the only factors associated with DFS. High tCD68 (HR 0.19) and sCD206 (HR 0.40) were associated with improved OS in P16+ OPSCC, but not in P16-. sCD163 and tCD163 infiltration was not related to adverse outcomes in P16+ nor in P16-. Table: 921P
Clinical and immunohistochemical characteristics
| P16- | P16+ | p value | |
| N | 39 | 19 | |
| mean Age (y, SD) | 58.8y (8.0) | 59.8y (8.8) | 0.65 |
| mDFS (months, 95%CI) | 14.4m (7.8-48)* | 158m (30-NR)* | ConclusionsIn this study, high tCD68 and sCD206 expression was associated with a better OS in OPSCC, albeit only in P16+ tumors. No concordance was found between CD163 and CD206 expression and both had a different prognostic impact. This illustrates the complexity of TIL-TAM interplay and the TAM spectrum diversity. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyGhent University Hospital. FundingGhent University Hospital Fonds voor Innovatie en Klinisch Onderzoek (FIKO). DisclosureM. Saerens: Financial Interests, Institutional, Invited Speaker: Pierre-Fabre, BMS, MSD; Financial Interests, Institutional, Advisory Board: Novartis, MSD. S. Rottey: Financial Interests, Institutional, Advisory Board: Pfizer, Merck, Roche, Ipsen, BMS; Financial Interests, Institutional, Invited Speaker: Ipsen, BMS, Astellas; Financial Interests, Institutional, Research Grant: MSD, Roche, BMS; Non-Financial Interests, Principal Investigator, It is my main task in the hospital to attract and perform clinical trials in oncology phase I-III: all companies performing clinical trials in oncology in Europe. All other authors have declared no conflicts of interest. Resources from the same session1015P - The efficacy and mechanism of pan-FGFR inhibitor (AZD4547) combined with immunoagonists or immunosuppressants in FGFR-positive tumorsPresenter: Qizhi Ma Session: Poster session 03 1016P - Phase I study of SOF10 plus atezolizumab in patients with advanced/recurrent solid tumoursPresenter: Toshihiko Doi Session: Poster session 03 1017P - Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)Presenter: Samuel Klempner Session: Poster session 03 1018P - Leveraging innate and adaptive immunity with AFM24 and atezolizumab in metastatic gastric cancerPresenter: Omar Saavedra Santa Gadea Session: Poster session 03 1019P - Bispecific PD1-IL2 antibody reshapes the inhibitory immune microenvironment of SMARCA4 mutant non-small cell lung cancer by reversing CD8+T cell exhaustionPresenter: Bo Cheng Session: Poster session 03 Resources: Abstract 1020P - Highly potent and specific bivalent T cell engager (TCE) targeting PRAME on HLA-A*02:01Presenter: Athanasia Dasargyri Session: Poster session 03 1021P - Chemotherapy and hypomethylating agents enhance anti-tumor activity of PRAME ImmTACPresenter: Adel Benlahrech Session: Poster session 03 1022P - A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)Presenter: Jonathan Riess Session: Poster session 03 1023P - Long-term follow up of patients treated with a DNA vaccine (pTVG-HP) for PSA-recurrent prostate cancerPresenter: Douglas McNeel Session: Poster session 03 1024P - Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumorsPresenter: Stephane Champiat Session: Poster session 03 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|